Form 4: Becton Dickinson Executive Trades BDX Shares

Thomas E. Polen Jr., Chairman, CEO, and President of Becton Dickinson & Co., reported significant stock transactions on June 1, 2026, including sales and acquisitions under a Rule 10b5-1 plan.

Summary

• Thomas E. Polen Jr., Chairman, CEO, and President of Becton Dickinson & Co. (BDX), executed a series of stock transactions on June 1, 2026.
• These transactions included the acquisition of 20,209 shares of common stock at $126.16 per share.
• Additionally, 17,445 shares were disposed of at $146.15 per share, and another 2,764 shares were disposed of at $146.35 per share.
• Following these transactions, Mr. Polen beneficially owns 108,235 shares directly.
• The transactions were conducted under a Rule 10b5-1 trading plan adopted on March 2, 2026.
• Stock appreciation rights (SARs) were also adjusted, with 20,209 SARs acquired at a price of $126.16, vesting in installments starting November 26, 2017, and expiring November 26, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While the executive is acquiring shares, they are also selling a significant amount, and the adjustments related to business combinations introduce some complexity.

Positives

• The acquisition of 20,209 shares at $126.16 per share indicates a belief in the company's future value by a key executive.
• The execution of a Rule 10b5-1 plan suggests a pre-determined, systematic approach to stock transactions, often viewed positively for its transparency and adherence to insider trading regulations.

Negatives

• The disposal of a significant number of shares (17,445 + 2,764 = 20,209 shares) at prices higher than the acquisition price could be interpreted as a signal of reduced confidence or a desire to realize gains by a key executive.

Risks

• The filing mentions adjustments to previously reported and unvested time-vested restricted stock units due to the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. This implies potential complexities and integration risks associated with business combinations.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance regarding future financial performance. However, the acquisition of shares and the existence of a Rule 10b5-1 plan suggest ongoing, planned stock activity by management.

Management Comments

• The reported transactions were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 2, 2026.
• Direct holdings reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of shares underlying previously reported and unvested time-vested restricted stock units held by the reporting person.
• Award terms reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp.

Industry Context

StockSavvy.ai notes that Form 4 filings by senior executives are common in the healthcare and life sciences sector, particularly for companies undergoing business combinations or strategic realignments. The use of Rule 10b5-1 plans is a standard practice for executives to manage their stock holdings in a compliant manner.

Stakeholder Impact

• Shareholders: The transactions may be interpreted in various ways, with the sale of shares potentially raising concerns, while the acquisition and the use of a 10b5-1 plan can be seen as orderly management of holdings.
• Employees: The adjustments to restricted stock units due to business combinations could affect employee compensation and equity awards.
• Creditors: No direct impact is indicated in this filing.

Next Steps

• Monitor future Form 4 filings from Thomas E. Polen Jr. and other Becton Dickinson executives for continued trading activity.
• Observe the impact of the business combination of Biosciences and Diagnostic Solutions with Waters Corp. on the company's performance.

Key Dates

Recommendation

The filing details routine stock transactions by a key executive under a pre-arranged plan. While the executive is acquiring some shares, the sale of a comparable number of shares, coupled with adjustments related to business combinations, suggests a balanced approach rather than a strong conviction for immediate price appreciation or depreciation. Therefore, a 'hold' recommendation is appropriate pending further operational or financial updates.

Keywords

Becton Dickinson, BDX, Form 4, Insider Trading, Stock Transaction, Rule 10b5-1, Thomas E. Polen Jr., Stock Appreciation Rights, Beneficial Ownership, SEC Filing